Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both fluoxetine and clomipramine are effective in treating psychogenic triggers of acral lick dermatitis in dogs, with fluoxetine leading to quicker recovery and lower recurrence rates, while clomipramine showed better overall recovery rates but was associated with fewer side effects.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study analyzed social media posts and found discrepancies between patient-reported satisfaction and emotional responses to alopecia areata treatments, highlighting potential gaps between perceived and clinical efficacy.

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

In this research, experienced clinicians noted inconsistency in the reproducibility of the commonly used Hamilton-Ludwig scales for assessing pattern hair loss severity in photographic assessments, leading to the proposal of a new 5-point scale for staging female hair loss.

The researchers reported that the facial Psoriasis Log-based Area and Severity Index (fPLASI) more reliably and sensitively captured clinical improvement in facial psoriasis than the existing facial Psoriasis Area and Severity Index (fPASI).

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study analyzed social media posts on alopecia areata treatments and found that while most reported perceived improvement, many treatments, particularly dexamethasone, were associated with underlying negative emotions.

This study reports that even minimal improvements in SLE-related fatigue and skin symptoms are meaningful to patients, supporting the content validity of the FACIT-Fatigue scale for measuring these effects.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This review discusses the development of the MATH+ treatment protocol for COVID-19 patients, detailing its scientific and clinical rationale, but reports no new experimental findings.

This abstract describes the Dermatologic Surgery journal, which publishes peer-reviewed articles on cosmetic and reconstructive skin surgery, but reports no new clinical findings.

This study describes a simple, noninvasive hair counting method used in a hair growth prevention trial, assessing its reliability and validity.

This article describes the diagnostic process and rewards of evaluating female hair loss but reports no new clinical findings.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

This publication reviews the World Professional Association for Transgender Health's Standards of Care for supporting transgender and gender nonconforming people, with adjustments needed for diverse global contexts and no new clinical results.

This article reviews the diagnosis and treatment of tinea capitis in children, noting that newer antifungal agents can offer effective systemic therapy alongside supportive topical treatments; it reports no new clinical findings.

This review discusses the integration of Artificial Intelligence in non-surgical cosmetic procedures, highlighting its potential to improve personalized aesthetic care and operational efficiency while addressing ethical and regulatory challenges; it presents no new clinical findings.

This review discusses the biology of hair follicles and common hair disorders in the elderly but reports no new clinical results.

This study found that in a 10-week trial, inositol did not significantly reduce trichotillomania symptoms compared to placebo, although 42.1% of inositol-treated patients felt 'much or very much improved' at the study's end.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.

This review found that oral methotrexate plus oral prednisone may improve disease activity or damage in juvenile active morphea compared to placebo plus prednisone, but adverse events may slightly increase.

This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.

This meeting underscored that hair testing is a crucial and evolving area in forensic and toxicological science, emphasizing advancements in analytical methods and its importance in public health and legal medicine.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study observed that the addition of Cuticapil Stem Hair Serum to standard care significantly improved hair growth and reduced hair shedding in patients with androgenetic alopecia, demonstrating superior efficacy compared to standard care alone without any reported adverse events.